The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

banner

The Medicines Company Wins Favorable Judgment in Angiomax® (Bivalirudin) Patent Litigation

28-Oct-2014 | Source : AG-IP News | Visits : 3954
PARSIPPANY, NJ - The Medicines Company announced in a press release the US District Court for the Northern District of Illinois in The Medicines Company v. Mylan, Inc. entered judgment in favor of The Medicines Company on all issues concerning US Patent No. 7,582,727 (the “’727 patent”). Following a June 2014 trial, Judge Amy St. Eve found all of the asserted claims (patent claims 1-3, 7-10, and 17) are infringed by Mylan’s Abbreviated New Drug Application (“ANDA”). The same claims were also found to be valid and enforceable.

“We are highly satisfied with the Illinois Court’s ruling, which supports our ongoing conviction to defend these patents vigorously,” said Clive Meanwell, Chairman and Chief Executive Officer for The Medicines Company.
Mylan’s ANDA seeks FDA approval to commercially manufacture, use or sell a generic version of The Medicines Company’s Angiomax® (bivalirudin) drug product before the expiration of the ’727 patent. The ruling prevents Mylan from obtaining FDA approval of its generic bivalirudin and launching its ANDA product until the earlier of a successful appeal or expiration of the ’727 patent in 2028. To appeal successfully, Mylan must overturn the Court’s rulings on each of the asserted claims.

The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: serious infectious disease care, acute cardiovascular care, and surgery and perioperative care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.
 
share



Related Articles